|
|
LETTER TO THE EDITOR |
|
Year : 2015 | Volume
: 63
| Issue : 5 | Page : 469-470 |
|
Intravitreal ziv-aflibercept for recurrent macular edema secondary to central retinal venous occlusion
Jay Chhablani
Smt. Kanuri Santhamma Retina Vitreous Centre, L. V. Prasad Eye Institute, Hyderabad, Telangana, India
Date of Web Publication | 2-Jul-2015 |
Correspondence Address: Jay Chhablani Smt. Kanuri Santhamma Retina Vitreous Centre, L. V. Prasad Eye Institute, Kallam Anji Reddy Campus, L. V. Prasad Marg, Banjara Hills, Hyderabad - 500 034, Telangana India
Source of Support: None, Conflict of Interest: None | Check |
DOI: 10.4103/0301-4738.159909
How to cite this article: Chhablani J. Intravitreal ziv-aflibercept for recurrent macular edema secondary to central retinal venous occlusion. Indian J Ophthalmol 2015;63:469-70 |
Dear Editor,
Recurrent macular edema (ME) secondary to central retinal venous occlusion (CRVO) is a challenging situation. Recently, newer anti-vascular endothelial growth factor (VEGF) drug, aflibercept (Eyelea ® , Bayer Healthcare, Germany), approved by Food and Drug Administration (FDA), has shown good treatment outcomes in randomized clinical trials in patients with ME secondary to CRVO. [1],[2] However, this drug is not available in India. Ziv-aflibercept (Zaltrap; Regeneron, New York, USA), anti-VEGF drug, is a recombinant fusion protein with a similar mechanism to aflibercept. It was approved by FDA in August 2012, for the treatment of resistant metastatic colorectal carcinoma. Recently, Mansour et al. reported intravitreal ziv-aflibercept as safe treatment at 4 weeks without any ocular toxicity in patients with diabetic ME and age-related macular degeneration, and they clarified the concerns about the osmolarity of this preparation. [3],[4] Here, we present a single case of off-label use of intravitreal Zaltrap ® in a patient with recurrent ME secondary to CRVO. Ethics committee approval was taken to report this case.
A 64-year-old male presented with a sudden vision loss in both eyes since 1-month. On examination, his best-corrected visual acuity was 20/160 in right and left eye respectively. He was diagnosed to have CRVO with ME and was treated with intravitreal bevacizumab in both eyes. His systemic investigations were within normal limits. During the follow-up of 20 months, he had multiple episodes of recurrent ME and received 12 and 13 anti-VEGF injections in right and left eye respectively, along with one intravitreal triamcinolone injection and peripheral panretinal photocoagulation in both eyes. After a treatment-free interval of 2 months that is, at 22 months of follow-up, he presented with recurrent edema in both eyes with of 20/200 in both eyes. On examination, there was ME in both eyes, with a central macular thickness (CMT) of 834 μ and 938 μ on optical coherence tomography (OCT) [Figure 1]a and b. In view of recurrent recalcitrant edema, after obtaining informed consent, he underwent intravitreal Zaltrap ® (1.25 mg in 0.05 ml) in both eyes under aseptic conditions, with an interval of 5 days between two eyes. The patient was subsequently followed at postinjection day 1, day 7 and day 30 (1-month). He did not have any symptoms of blurred vision or ocular pain related to injection without any signs of inflammation/toxicity. At 1-month follow-up, his visual acuity improved to 20/100 and 20/159 in his right and left eye respectively. OCT showed a decrease in edema with CMT of 193 μ and 232 μ [Figure 1]c and d in right and left eye respectively. As there was no observed clinical toxicity at 1-month follow-up and good clinical response, the patient has been advised to undergo another injection of Zaltrap ® in both eyes. | Figure 1: Top panel shows severe cystoid macular edema (ME) on spectral domain optical coherence tomography in the right eye (OD) and the left eye (OS) before intravitreal ziv-aflibercept injection. Bottom panel shows significant decrease in ME at 1-month follow-up in both eyes
Click here to view |
This is the first report of intravitreal Zaltrap ® in eyes with ME secondary to CRVO. Our report presents evidence supporting the clinical safety and efficacy of a single intravitreal Zaltrap ® injection and supports its use as the primary or second line of anti-VEGF therapy in recalcitrant ME due to CRVO. However, further studies are warranted to evaluate the long-term safety and efficacy of this drug in various situations where anti-VEGF therapy is indicated.
References | | |
1. | Mansour AM, Al-Ghadban SI, Yunis MH, El-Sabban ME. Ziv-aflibercept in macular disease. Br J Ophthalmol 2015, [Epub ahead of print]. |
2. | Calugaru D, Calugaru M. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. Am J Ophthalmol 2015;159:607-8. |
3. | Ogura Y, Roider J, Korobelnik JF, Holz FG, Simader C, Schmidt-Erfurth U, et al. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. Am J Ophthalmol 2014;158:1032-8. |
4. | Marmor MF, Martin LJ, Tharpe S. Osmotically induced retinal detachment in the rabbit and primate. Electron miscoscopy of the pigment epithelium. Invest Ophthalmol Vis Sci 1980;19:1016-29. [ PUBMED] |
[Figure 1]
This article has been cited by | 1 |
An Update on Strategies to Deliver Protein and Peptide Drugs to the Eye |
|
| Sai H. S. Boddu, Devarshi Acharya, Vivek Hala, Harshil Jani, Sonal Pande, Chirag Patel, Moyad Shahwan, Renukuntla Jwala, Ketan M. Ranch | | ACS Omega. 2023; 8(39): 35470 | | [Pubmed] | [DOI] | | 2 |
Efficacy of intravitreal ziv-aflibercept in patients with macular edema following retinal vein occlusion in Korle-Bu Teaching Hospital, Ghana: a retrospective case series |
|
| Imoro Zeba Braimah, Kofi Agyabeng, Winfried M. Amoaku | | International Ophthalmology. 2021; 41(7): 2445 | | [Pubmed] | [DOI] | | 3 |
In vitro response and gene expression of human retinal Müller cells treated with different anti-VEGF drugs |
|
| Javier Cáceres-del-Carpio, M. Tarek Moustafa, Jaime Toledo-Corral, Mohamed A. Hamid, Shari R. Atilano, Kevin Schneider, Paula S. Fukuhara, Rodrigo Donato Costa, J. Lucas Norman, Deepika Malik, Marilyn Chwa, David S. Boyer, G. Astrid Limb, M. Cristina Kenney, Baruch D. Kuppermann | | Experimental Eye Research. 2020; 191: 107903 | | [Pubmed] | [DOI] | | 4 |
Ziv-aflibercept: A cost-effective, off-label, highly potent antagonist of vascular endothelial growth factor |
|
| Ahmad M. Mansour, Michael W. Stewart, Michel E. Farah, Hana A. Mansour, Jay Chhablani | | Acta Ophthalmologica. 2020; 98(5) | | [Pubmed] | [DOI] | | 5 |
RETRACTED ARTICLE: Pharmacological agents in development for diabetic macular edema |
|
| Mohammad Ali Sadiq, Muhammad Sohail Halim, Muhammad Hassan, Neil Onghanseng, Irmak Karaca, Aniruddha Agarwal, Rubbia Afridi, Yasir J. Sepah, Diana V. Do, Quan Dong Nguyen | | International Journal of Retina and Vitreous. 2020; 6(1) | | [Pubmed] | [DOI] | | 6 |
Comparison of Loading Doses of Ziv-Aflibercept and Aflibercept in Neovascular Age-Related Macular Degeneration |
|
| Apoorva Ayachit, Sumit Randhir Singh, Anand Subramanyam, Sarvesh Tiwari, Abhishek Heranjal, Goura Chattannavar, Priti Pandey, Haitham Salti, Mohamad A Mansour, Ahmad Mansour, Jay Chhablani | | Asia-Pacific Journal of Ophthalmology. 2020; 9(2): 144 | | [Pubmed] | [DOI] | | 7 |
INTRAVITREAL INJECTIONS OF ZIV-AFLIBERCEPT FOR THE TREATMENT OF A PATIENT WITH MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION |
|
| Gabriel Costa de Andrade, João Rafael de Oliveira Dias, André Maia, Michel Eid Farah, Somaia Mitne, Eduardo Büchele Rodrigues | | RETINAL Cases & Brief Reports. 2018; 12(2): 93 | | [Pubmed] | [DOI] | | 8 |
Two-year outcomes of intravitreal ziv-aflibercept |
|
| Ahmad M Mansour, Mohammed Ashraf, Abdulrazzak Charbaji, Muhammad H Younis, Ahmed A Souka, Avantika Dogra, Hana A Mansour, Jay Chhablani | | British Journal of Ophthalmology. 2018; 102(10): 1387 | | [Pubmed] | [DOI] | | 9 |
Safety and Efficacy of Ziv-Aflibercept in the Treatment of Refractory Diabetic Macular Edema |
|
| Mohammed Ashraf, Hassan El Kayal, Ahmed A. R. Souka | | Ophthalmic Surgery, Lasers and Imaging Retina. 2017; 48(5): 399 | | [Pubmed] | [DOI] | | 10 |
CLINICAL AND ELECTROPHYSIOLOGICAL EVALUATION AFTER INTRAVITREAL ZIV-AFLIBERCEPT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION |
|
| João Rafael de Oliveira Dias, Gabriel Costa de Andrade, Vinicius Ferreira Kniggendorf, Eduardo Amorim Novais, André Maia, Carsten Meyer, Sung Eun Song Watanabe, Michel Eid Farah, Eduardo Büchele Rodrigues | | Retina. 2017; 37(8): 1499 | | [Pubmed] | [DOI] | | 11 |
SHORT-TERM SAFETY OF 2 MG INTRAVITREAL ZIV-AFLIBERCEPT |
|
| Jay Chhablani, Chintan Jethalal Dedhia, Hari K. Peguda, Michael Stewart | | Retina. 2017; 37(10): 1859 | | [Pubmed] | [DOI] | | 12 |
FLATTENING OF A TREATMENT-RESISTANT RETINAL PIGMENT EPITHELIAL DETACHMENT AFTER A SINGLE INTRAVITREAL INJECTION OF ZIV-AFLIBERCEPT |
|
| Rohit Yogi, Michael Stewart, Jay Chhablani | | RETINAL Cases & Brief Reports. 2017; 11(2): 111 | | [Pubmed] | [DOI] | | 13 |
Two Doses of Intravitreal Ziv-Aflibercept versus Bevacizumab in Treatment of Diabetic Macular Edema: A Three-Armed, Double-Blind Randomized Trial |
|
| Ahmadreza Baghi, Mohammad Hossein Jabbarpoor Bonyadi, Alireza Ramezani, Mohsen Azarmina, Siamak Moradian, Mohammad Hossein Dehghan, Ramin Nourinia, Gholam A. Peyman, Mehdi Yaseri, Masoud Soheilian | | Ophthalmology Retina. 2017; 1(2): 103 | | [Pubmed] | [DOI] | | 14 |
The world is your oyster! |
|
| Sundaram Natarajan | | Indian Journal of Ophthalmology. 2016; 64(11): 793 | | [Pubmed] | [DOI] | | 15 |
Comment on: Intravitreal ziv-aflibercept for recurrent macular edema secondary to central retinal venous occlusion |
|
| Alok Sen, Ashish Mitra, PawanPuneet Malhotra, Sonal Gupta | | Indian Journal of Ophthalmology. 2015; 63(9): 751 | | [Pubmed] | [DOI] | |
|
|
|
|